SMARTERyellowpages.com Listing for Aerogen Inc

Home Click Here to Add a Listing Business Solutions Smarter AdWords Advertising Program Disclaimer Top 200 Categories Contact FAQ Glossary

Always free listings...
Always

Search Tips Current city: All Cities

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z <<< click letter to list yellow page categories

Home > Categories brought to you by the letter L > Listings under Laboratories-Pharmaceutical >
Results: Listing for Aerogen Inc

	Click here to explore the website of Aerogen Inc (214-) 1310 Orleans Dr (click for map) Sunnyvale, CA 94089 (408) 543-2400 Click here to email Aerogen Inc	Aerogen Inc is one of Deloitte & Touche's 2001 50 fastest growing technology companies in Silicon Valley
	Our goal is to become the leading provider of aerosol-based pulmonary drug delivery products. Our goal is to become the leading provider of aerosol-based pulmonary drug delivery products. Key elements of our strategy include: Incorporating our core technology into adaptable delivery platforms Developing our platforms for multiple product applications Developing and commercializing respiratory products ourselves and with partner companies Partnering with pharmaceutical and biotechnology companies for systemic delivery products Out-licensing our technology for use outside the field of pulmonary drug delivery We intend to create and market a respiratory disease product portfolio. Our initial products will focus on treating three respiratory diseases--asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF)--and will improve treatment for patients currently using nebulizers and those receiving therapy via ventilators. These products will deliver commercially available respiratory drugs and compounds licensed from third parties. In 1999 the U.S. institutional and pharmacy expenditures for inhaled respiratory medications were approximately $3.3 billion. We also are developing respiratory products in collaboration with partner companies who will commercialize those products. We have an agreement with PathoGenesis Corporation to develop a small, hand-held Aerodose™ inhaler to deliver TOBI®, an inhaled tobramycin treatment for CF. Under the agreement, PathoGenesis received exclusive worldwide rights to commercialize our Aerodose inhaler for use in combination with TOBI. In August 2000, PathoGenesis announced that it had entered into an agreement to be acquired by Chiron Corporation, a leading biotechnology company. In addition to our respiratory therapy activities, we intend to develop novel pulmonary drug delivery products for systemic drug delivery. These products will be developed in collaboration with pharmaceutical and biotechnology companies. Our first product in development for delivery of drugs through the lungs to the bloodstream is an Aerodose inhaler delivering insulin to treat diabetes. We completed our first clinical trial for this product, and are proceeding with additional trials in the United States and Europe. We have an agreement with Becton, Dickinson and Company (BD) under which BD is developing and will supply a patient-adjustable container for use in our Aerodose insulin product. We plan to partner this product for further development, clinical testing and commercialization. We estimate that the worldwide insulin market will grow from $3.2 billion in 2000 to $6.5 billion by 2005. The worldwide market for therapeutic proteins is estimated to be $19.2 billion in 2001. We believe that systemic drug delivery of these molecules via the lungs provides significant additional market opportunities for us.

Send SMARTERyellowpages.com your feedback (about the above Listing)
If you have different information about this Listing or were unable to contact them please let us know by clicking on the above link.
Click here to insert your Listing's URL for your Smarter AdWords Ad